Document Detail

OKT3-induced hypotension in heart allograft recipients treated for steroid-resistant rejection.
MedLine Citation:
PMID:  2651620     Owner:  NLM     Status:  MEDLINE    
OKT3 (a murine antihuman mature T cell antibody) has become an important therapeutic agent for the treatment of acute allograft rejection unresponsive to corticosteroid therapy. Seven heart allograft recipients received eight 10-day courses (one retreatment) of OKT3 for steroid-resistant rejection. All patients underwent hourly monitoring of vital signs, and one of the patients underwent hemodynamic monitoring during therapy. Age- and sex-matched kidney allograft recipients (including one retreated patient) undergoing the identical OKT3 antirejection protocol served as control patients. All patients had a measured decrease in arterial pressure during OKT3 therapy. The time from first dose to peak hypotensive response was identical in both heart and kidney allograft recipients (31 +/- 11 versus 32 +/- 11 hours, respectively, p = not significant [NS]) and did not coincide with the peak febrile response (22 +/- 12 versus 27 +/- 13 hours, respectively, p = NS). The decrease in mean arterial pressure was significantly greater in the heart allograft patients compared with the kidney allograft recipients (39 +/- 17 versus 22 +/- 10 mm Hg, respectively, p less than 0.03), despite a slightly greater positive fluid balance in the heart allograft recipients (1333 +/- 1991 versus 715 +/- 1224 ml, p = NS). The change in heart rate associated with the hypotension was only slightly and not significantly greater in the kidney allograft recipients. In the one heart allograft recipient undergoing hemodynamic monitoring, the decrease in mean arterial pressure was initially paralleled by a decline in systemic vascular resistance.(ABSTRACT TRUNCATED AT 250 WORDS)
J D Hosenpud; D J Norman; G A Pantely; A M Cobanoglu; A Starr
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of heart transplantation     Volume:  8     ISSN:  0887-2570     ISO Abbreviation:  J Heart Transplant     Publication Date:    1989 Mar-Apr
Date Detail:
Created Date:  1989-05-26     Completed Date:  1989-05-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8604172     Medline TA:  J Heart Transplant     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  159-65; discussion 165-6     Citation Subset:  IM    
Cardiac Transplant Program, Oregon Health Sciences University, Portland 97210.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal / adverse effects*
Antigens, Surface / immunology*
Graft Rejection*
Heart / physiopathology
Heart Transplantation*
Hypotension / etiology*,  physiopathology
Middle Aged
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal; 0/Antigens, Surface

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary artery spasm in heart transplant recipients.
Next Document:  Neopterin as a new marker to detect acute rejection after heart transplantation.